VRTX Financial Facts
Sales, general and administrative expenses: 106.06MNet loss attributable to Vertex: -38.84M
See Full Income Statement
Accounts receivable, net: 182.23M
Noncontrolling interest (Alios): 186.8M
See Full Balance Sheet
Vertex Pharmaceuticals Incorporated (VRTX) Earnings
|
Expand Research on VRTX
| Next EPS Date | 8/3/26 | EPS Growth Rate | +4.4% |
|---|---|---|---|
| Average EPS % Beat Rate | +3.3% | Revenue Growth Rate | +8.8% |
| Average % Move 1-Wk after EPS | -4.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/3/26  |
Q226 | N/A | $4.72 | N/A | N/A | $3.22B | = | N/A | N/A | ||
| 5/4/26 | Q126 | $4.47 | $4.33 | +$0.14 | $2.99B | $3.03B | = |  | | Details | |
| 2/12/26 | Q425 | $5.03 | $5.08 | -$0.05 | $3.19B | $3.18B | = | | | Details | |
| 11/3/25 | Q325 | $4.80 | $4.57 | +$0.23 | $3.08B | $3.05B | = | | | Details | |
| 8/4/25 | Q225 | $4.52 | $4.27 | +$0.25 | $2.96B | $2.91B | = | | | Details | |
| 5/5/25 | Q125 | $4.06 | $4.26 | -$0.20 | $2.77B | $2.86B | = | | | Details | |
| 2/10/25 | Q424 | $3.98 | $4.02 | -$0.04 | $2.91B | $2.79B | = | | | Details | |
| 11/4/24 | Q324 | $4.38 | $4.08 | +$0.30 | $2.77B | $2.69B | = | | | Details |
